Supplementary Fig.S4 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers
Key Points
Key points are not available for this paper at this time.
Abstract
Characterization of 9MW2821.
AIに質問
Like
Bookmark
Share
AIに質問
Like
Bookmark
Share
Supplementary Fig.S4 from Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for treatment of Nectin-4-expressing Cancers | Synapse